Publications
117
Citations
3,786
Est. group size
~1
Recurring co-author estimate
Active years
34
Publishing since 1991
Karl A. Werbovetz's research focuses on discovering and characterizing new drug candidates against parasitic diseases, especially leishmaniasis (a tropical disease caused by Leishmania parasites) and related infections like Chagas' disease. His work combines chemical synthesis of new compounds (such as arylimidamides, azoles, and triazoles) with biological testing to understand how these molecules kill parasites, including studies of parasite enzymes like CYP5122A1 and CYP51 that are involved in building the parasite's cell membrane sterols. He also studies drug formulation and delivery methods, such as nanovesicles and microneedles, to improve treatment of these diseases.
Publication output has been modest and somewhat irregular over the last decade, peaking around 2020 and slowing to about one paper per year in recent years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- CYP5122A1 encodes an essential sterol C4-methyl oxidase in Leishmania donovani and determines the antileishmanial activity of antifungal azoles
Nature Communications · 2024
- N-substituted-4-(pyridin-4-ylalkyl)piperazine-1-carboxamides and related compounds as Leishmania CYP51 and CYP5122A1 inhibitors
Bioorganic & Medicinal Chemistry · 2024
- CYP5122A1 encodes an essential sterol C4-methyl oxidase in Leishmania donovani and determines the antileishmanial activity of antifungal azoles
Research Square · 2023
- Sterol profiling of Leishmania parasites using a new HPLC-tandem mass spectrometry-based method and antifungal azoles as chemical probes reveals a key intermediate sterol that supports a branched ergosterol biosynthetic pathway
International Journal for Parasitology Drugs and Drug Resistance · 2022
- Imidazoles as Potential Anticancer Agents: An Update on Recent Studies
Molecules · 2021
- Synthesis and Antileishmanial Evaluation of Arylimidamide–Azole Hybrids Containing a Phenoxyalkyl Linker
ACS Infectious Diseases · 2021
- FORMULATION AND EVALUATION OF AMPHOTERICIN B AND MILTEFOSINE COMBINATION NANOVESICLES
International Journal of Applied Pharmaceutics · 2021
- Synthesis and Antiprotozoal Activity of Cationic 1,4-Diphenyl-1 H -1,2,3-triazoles
Figshare · 2020
- Novel Arylimidamides for Treatment of Visceral Leishmaniasis
UNC Libraries · 2020
- A Novel Tropically Stable Oral Amphotericin B Formulation (iCo-010) Exhibits Efficacy against Visceral Leishmaniasis in a Murine Model
UNC Libraries · 2020
- Evaluation of Arylimidamides DB1955 and DB1960 as Candidates against Visceral Leishmaniasis and Chagas' Disease: In Vivo Efficacy, Acute Toxicity, Pharmacokinetics, and Toxicology Studies
UNC Libraries · 2020
- Antileishmanial Activities of Several Classes of Aromatic Dications
UNC Libraries · 2020
- Microneedle-Based Delivery of Amphotericin B for Treatment of Cutaneous Leishmaniasis
Biomedical Microdevices · 2019
- Synthesis and antileishmanial evaluation of thiazole orange analogs
Bioorganic & Medicinal Chemistry Letters · 2019
- CCDC 1920794: Experimental Crystal Structure Determination
The Cambridge Structural Database · 2019
- UNC Libraries×4
- Bioorganic & Medicinal Chemistry Letters×2
- Antimicrobial Agents and Chemotherapy×2
- Molecules×1
- Journal of Natural Products×1
- Dawn M. Wetzel
Medicine · Purdue University West Lafayette
- Bradford S. McGwire
Medicine · The Ohio State University
- Abhay R. Satoskar
Medicine · The Ohio State University
- Christine A. Petersen
Medicine · The Ohio State University
- Fabiano Borges Figueiredo
Medicine · Purdue University West Lafayette
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile